Advertisement

Advertisement
Prostate Cancer

Polygenic Risk Score for Prostate Cancer Screening

In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than screening with prostate-specific antigen (PSA) and magnetic resonance imaging (MRI).

 

Colorectal Cancer

Benefits of Walnut Consumption: Curbing Inflammation, Colorectal Cancer Risk

Researchers have uncovered that eating walnuts may improve systemic inflammation and reduce the risk for colorectal cancer, according to a recent study published by Moussa et al in Cancer Prevention Research.

Breast Cancer

Patient Support Found for AI Use as Second Reader of Mammograms

A survey study has shown cautious patient support for the use of artificial intelligence (AI) as a second reader in screening mammograms, according to results published in Radiology: Imaging Center 


Advertisement
Multiple Myeloma

Addition of Daratumumab to Treatment Regimen in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

As reported in The Lancet Oncology by Mateos et al, the final results of the phase III ALCYONE trial showed persistent benefit with the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma. The primary analysis of the trial showed that D-VMP significantly improved progression-free survival vs VMP in this setting.  

Kidney Cancer

Extended Follow-up of Belzutifan Treatment for von Hippel–Lindau Disease–Associated Renal Cell Carcinoma

In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al found that use of the hypoxia-inducible factor-2α inhibitor belzutifan was associated with maintained benefit in patients with von Hippel–Lindau disease–associated renal cell carcinoma.

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Breast Cancer

Raising Awareness of Inflammatory Breast Cancer

In late January 2013, while playing with my young son, I noticed my left breast seemed slightly larger than my right breast. Although, at the time, I had no idea this type of swelling is a hallmark of inflammatory breast cancer, a rare and aggressive disease, I immediately made an appointment with...

Advertisement

Omission of Endocrine Therapy in Estrogen Receptor–Low, Early-Stage Breast Cancer

In a study reported in the Journal of Clinical Oncology, Choong et al found that omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early-stage breast cancer was not associated with improved survival outcomes. The study used National Cancer...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Issues in Oncology

Executive Orders and Cancer Care

The Association for Clinical Oncology (ASCO) is working to understand the extent and scope of several recent executive actions. ASCO recognizes the concern and confusion many are currently experiencing and understands that if there are interruptions in care and research, there can be negative...

Hepatobiliary Cancer

Combination Immunotherapy Approved for Unresectable or Metastatic Hepatocellular Carcinoma

On April 11, 2025, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma. (See here for details on approval of this combination immunotherapy for colorectal...

Childhood Exposure to Bacterial Toxin May Trigger Early-Onset Colorectal Cancer

Researchers may have identified the bacterial toxin colibactin as a potential factor contributing to the concerning rise in early-onset colorectal cancer, according to a novel study published by Díaz-Gay et al in Nature. The findings demonstrated a substantial enrichment of colibactin-related...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Neuroendocrine Tumors

Cabozantinib Approved for Treatment of Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) recently approved the tyrosine kinase inhibitor cabozantinib (Cabometyx) for adult and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors...

Advertisement

Use of Statins in CLL/SLL

Statin use during targeted therapy treatment led to a 61% improvement in the risk of dying of cancer for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to the results of a study published in Blood Advances. The investigators sought to determine the...

ASCO Post X Feed
Social Media Hub by Everwall